Serum Antibodies for Diagnosis of Inflammatory Bowel Disease
Customize your policy alerts
Sign up for all eocco policy alerts
Know when eocco releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage, and coding for serum antibody panels (e.g., ASCA, ANCA), TPMT genotyping/phenotyping, thiopurine metabolite monitoring, and related tests used to diagnose or manage inflammatory bowel disease (IBD). Applies to providers ordering these tests for members of the payer (eocco).
No material clinical or coverage changes in this revision.
Coverage Criteria
TPMT baseline testing — Covered indications
Covered when ANY one of the following is met (baseline TPMT genotype testing is covered one time during the patient's lifetime):
Covered one time during the patient's lifetime
Thiopurine metabolite monitoring — Covered indications
Monitoring of thiopurine metabolite levels is considered medically necessary when ANY one of the following indications is met:
Serologic antibody tests and biologic drug level/antibody tests — Not covered / Experimental or Investigational
The following tests are considered experimental, investigational, or unproven for diagnosis of IBD, differentiating UC vs CD, or for management unless otherwise stated:
Listed as experimental/investigational for these indications; note ASMA may be medically necessary for autoimmune hepatitis diagnosis
Listed as experimental/investigational for measurement of therapeutic drug antibodies or drug levels for management of IBD
Anti-smooth muscle antibodies (ASMA) are explicitly listed as experimental and investigational when used to diagnose inflammatory bowel disease or to distinguish ulcerative colitis from Crohn’s disease because their effectiveness for those indications has not been established. The policy notes that ASMA may be medically necessary for the separate indication of diagnosing autoimmune hepatitis, but not for IBD diagnostic differentiation.
These extracted sections do not provide additional, test‑specific coverage criteria or exclusions beyond the policy statements; providers must follow applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and the health plan’s discretion for any indications not explicitly addressed in this policy. Reference the Medicare Benefit Policy Manual, Chapter 15 §50 and the CMS coverage database when Medicare rules apply.
Serologic antibody panels including ASCA (anti‑Saccharomyces cerevisiae antibodies), ANCA (anti‑neutrophil cytoplasmic antibodies), and other listed markers (ACCA, ALCA, AMCA, Anti‑C, Anti‑L, OmpC, anti‑Cbir1, multi‑antibody panels, and Prometheus IBD sgi) are considered experimental, investigational, or unproven for the purposes of diagnosing IBD or distinguishing ulcerative colitis from Crohn’s disease. Likewise, measurement of antibodies to biologic therapies or measurement of serum drug levels and commercial assays (for example, Anser IFX, Anser ADA, Anser VDZ, Anser UST) are considered experimental/investigational for these diagnostic and management indications.
No additional coverage notes are stated in the extracted sections for this placeholder. Where Medicare Part B rules or other NCDs/LCDs apply, follow those coverage and authorization requirements and any plan‑specific discretion for coverage decisions.
Coding and Billing
| 83789 | TPMT mass spectrometry and tandem mass spectrometry, qualitative or quantitative (listed as not covered) |
| 86256 | Fluorescent noninfectious agent antibody; titer, each antibody (listed as not covered) |
| 80299 | Quantification of therapeutic drug, not elsewhere specified (listed as not covered) |
| 82397 | Chemiluminescent assay (listed as not covered for listed antibody panels) |
| 83516 | Immunoassay for analyte other than infectious agent antibody or antigen (listed as not covered) |
| 83519 | Immunoassay, analyte, quantitative; not otherwise specified (RIA) (listed as not covered) |
| 83520 | Immunoassay, analyte, quantitative; not otherwise specified (listed as not covered) |
| 86021 | Antibody identification; leukocyte antibodies [ANCA antibodies] (listed as not covered) |
| 86255 | Fluorescent noninfectious agent antibody; screen, each antibody (listed as not covered) |
| 86671 | Antibody; fungus, not elsewhere specified (listed as not covered) |
| Jurisdictions 5, 8 | Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD) |
| F (2 & 3) | MAC jurisdiction covering AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ; Contractor: Noridian Healthcare Solutions, LLC |
Provider Actions and Requirements
Prior authorization documentation required
Prior authorization requests must be accompanied by clinical documentation that supports medical necessity, including specialist chart notes, the ordering provider’s history & physical, results of colonoscopy and other diagnostic studies performed, and the pathology report.
- Chart notes and history & physical from the ordering specialist
- Results of colonoscopy and other diagnostic studies performed
- Pathology report
Plan discretion and NCD/LCD adherence
Additional indications not explicitly listed in this policy may be covered at the discretion of the health plan. Where applicable, providers must follow any relevant National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) for coverage and authorization rules.
- Additional indications may be covered at plan discretion
- Follow applicable NCDs and LCDs for coverage/authorization rules
Step therapy not specified
No step therapy requirements are specified in this policy for the tests and indications covered.
Provider action (reserved)
Reserved: no additional provider-action text was extracted for this item in the source materials.
Information required with prior authorization
Prior authorization requests must include supporting clinical records: specialist chart notes and history & physical, results of colonoscopy and other diagnostic studies performed, and the pathology report to substantiate the request.
- Chart notes and history & physical from the ordering specialist
- Results of colonoscopy and other diagnostic studies performed
- Pathology report
Denial risk for non‑covered indications
Requests for testing that do not meet the policy’s medical necessity criteria — for example baseline TPMT testing or thiopurine metabolite monitoring when the listed indications are not met, or requests for tests designated experimental/investigational (such as ASCA or ANCA for IBD diagnosis) — may be denied.
- Baseline TPMT testing must meet the covered indications (one-time baseline to determine candidacy prior to thiopurine initiation or in patients with abnormal CBC not responsive to dose reduction)
- Thiopurine metabolite monitoring must meet the listed indications (suspected toxicity or lack of response)
- Tests listed as experimental/investigational for IBD diagnosis or management (e.g., ASCA, ANCA) are subject to denial if requested for those indications
NCD/LCD compliance required
Claims and authorization requests must comply with any applicable NCDs and LCDs; failure to follow NCD/LCD requirements where they apply may result in claim denials or recoupment.
- Comply with applicable National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs)
- Noncompliance with NCD/LCD may lead to denial or recoupment
Medicare documentation and NCD/LCD reference
When Medicare guidance is relevant, providers should reference the Medicare Benefit Policy Manual, Chapter 15 §50 (Drugs and Biologicals) and any applicable NCDs/LCDs for outpatient (Part B) drugs and related coverage rules.
- Medicare Benefit Policy Manual, Pub. 100-2, Chapter 15, §50
- Check the CMS Medicare Coverage Database for applicable NCDs/LCDs
Background
Inflammatory bowel disease (IBD) encompasses ulcerative colitis (UC) and Crohn’s disease (CD). Diagnosis is established primarily through radiographic, endoscopic, and histologic evaluation rather than by serologic testing. Serologic markers such as ANCA and ASCA have been investigated to assist in differentiating UC and CD but the policy states they lack sufficient established effectiveness for definitive diagnosis. In contrast, assessment of thiopurine metabolism is clinically relevant: TPMT genotype or phenotype testing is recommended prior to initiating azathioprine or 6‑mercaptopurine to determine candidacy and guide dosing (covered one time during the patient’s lifetime), and measurement of thiopurine metabolites is medically necessary when monitoring for suspected toxicity or lack of therapeutic response.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.